Get the Stockscreener App
1.31
0.77%
0.01
Nextcure Inc stock is traded at $1.31, with a volume of 22,134.
It is up +0.77% in the last 24 hours and down -2.24% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
See More
Previous Close:
$1.30
Open:
$1.32
24h Volume:
22,134
Relative Volume:
0.61
Market Cap:
$38.09M
Revenue:
-
Net Income/Loss:
$-61.28M
P/E Ratio:
-0.5198
EPS:
-2.52
Net Cash Flow:
$-46.46M
1W Performance:
-2.24%
1M Performance:
-2.24%
6M Performance:
-21.56%
1Y Performance:
+6.50%
1-Day Range:
$1.3047
$1.33
1-Week Range:
$1.28
$1.40
52-Week Range:
$1.03
$2.57
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| NXTC | 1.3132 | 38.09M | 0 | -61.28M | -46.46M | -2.52 |
| VRTX | 448.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.39 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.08 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.00 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.80 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - The Manila Times
NextCure's NC605 Shows 90% Fracture Prevention in Breakthrough Bone Disease Study | NXTC Stock News - StockTitan
Logos Global Management LP Reduces Stake in NextCure Inc - GuruFocus.com
Affinity Asset Advisors, LLC Increases Stake in NextCure Inc - GuruFocus.com
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation - Simply Wall St
NextCure Reports Improved Financial Performance and Strategic Focus - TipRanks
National Presto Industries, Inc. (NYSE:NPK) Shares Sold by State of Alaska Department of Revenue - Defense World
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clin - WICZ
NextCure (NASDAQ:NXTC) Shares Down 3.6% – Here’s Why - Defense World
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
Elevation Capital Advisory LLC Purchases New Shares in Vanguard Information Technology ETF (NYSEARCA:VGT) - americanbankingnews.com
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
NextCure, Inc. (NASDAQ:NXTC) Shares Purchased by Logos Global Management LP - Defense World
Next plc Executes Share Buyback Program - TipRanks
Nexteq PLC Announces Share Buyback and Voting Rights Update - TipRanks
Next PLC Executes Share Buy-Back for Cancellation - TipRanks
Next plc Conducts Share Buyback and Cancellation - TipRanks
Next lifts profit guidance to almost £1bn - Investors Chronicle
Next PLC’s Fresh Guidance Lift, Overseas Plans Boost Shares - The Wall Street Journal
Next PLC Impresses Investors with Yet Another Guidance Upgrade - TipRanks
Next is approaching a historic profit landmark- what is driving this growth? - Proactive Investors Australia
Next Shares Rise 3% As Full-Year Estimates Hiked - Forbes
Next shares rise on upbeat full-year profit outlook By Investing.com - Investing.com South Africa
Record high for Next shares after guidance raised again - Interactive Investor
Next Lifts Profit Target Again as Autumn Fashion Sales Surge - BNN Bloomberg
UK's Next raises forecast to put 1 billion pound profit in sight - Reuters
Britain's Next on track for 1 billion pounds annual profit - Marketscreener.com
Next Raises FY Pre-Tax Profit Guidance By £15 Mln - XM
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 - ForexTV.com
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Assenagon Asset Management S.A. Sells 864 Shares of Stantec Inc. (NYSE:STN) - Defense World
Assenagon Asset Management S.A. Buys 131 Shares of Watsco, Inc. (NYSE:WSO) - Defense World
Assenagon Asset Management S.A. Sells 473,491 Shares of U.S. Silica Holdings, Inc. (NYSE:SLCA) - Defense World
Vanguard Group Inc. Raises Stock Holdings in NextCure, Inc. (NASDAQ:NXTC) - Defense World
NextCure (NASDAQ:NXTC) Stock Rating Reaffirmed by Needham & Company LLC - Defense World
NextCure, Inc. (NASDAQ:NXTC) Sees Significant Drop in Short Interest - Defense World
NextCure (NASDAQ:NXTC) Trading Down 3.6% - Defense World
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate - Simply Wall St
Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui - openPR
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Quantisnow
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference - Quantisnow
NextCure to Present at the JMP Securities Life Sciences Conference - Quantisnow
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference - Quantisnow
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody ... - Quantisnow
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual ... - Quantisnow
NextCure to Present at the Ladenburg Thalmann Healthcare Conference - Quantisnow
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference - Quantisnow
What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares? - Yahoo Movies Canada
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - ForexTV.com
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):